Article
Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.
Science translational medicine - 22 Jan 2014
Childers Martin K, Joubert Romain, Poulard Karine, Moal Christelle, Grange Robert W, Doering Jonathan A, Lawlor Michael W, Rider Branden E, Jamet Thibaud, Danièle Nathalie, Martin Samia, Rivière Christel, Soker Thomas, Hammer Caroline, Van Wittenberghe Laetitia, Lockard Mandy, Guan Xuan, Goddard Melissa, Mitchell Erin, Barber Jane, Williams J Koudy, Mack David L, Furth Mark E, Vignaud Alban, Masurier Carole, Mavilio Fulvio, Moullier Philippe, Beggs Alan H, Buj-Bello Anna
Abstract excerpt
Loss-of-function mutations in the myotubularin gene (MTM1) cause X-linked myotubular myopathy (XLMTM), a fatal, congenital pediatric disease that affects the entire skeletal musculature. Systemic administration of a single dose of a recombinant serotype 8 adeno-associated virus (AAV8) vector expressing murine myotubularin to Mtm1-deficient knockout mice at the onset or at late stages of the disease resulted in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
